Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 16958630 | ANTIBODY-MODIFIED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELL AND USES THEREOF | January 2021 | March 2025 | Allow | 57 | 1 | 1 | Yes | No |
| 17253956 | ADENO-ASSOCIATED VIRUS VECTOR DELIVERY OF MUSCLE SPECIFIC MICRO-DYSTROPHIN TO TREAT MUSCULAR DYSTROPHY | December 2020 | March 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17125930 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | December 2020 | July 2023 | Allow | 31 | 1 | 0 | No | No |
| 17124667 | A method of cell therapy | December 2020 | January 2025 | Allow | 49 | 1 | 1 | Yes | No |
| 17122562 | HAPLOID HUMAN EMBRYONIC STEM CELL LINES AND SOMATIC CELL LINES AND METHODS OF MAKING THE SAME | December 2020 | May 2024 | Allow | 41 | 1 | 1 | No | No |
| 17251360 | CROSS-LINKABLE CELLULOSE AS 3D PRINTING MATERIAL | December 2020 | May 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17101785 | ANTI-CD19 CAR-T CELL | November 2020 | December 2024 | Allow | 49 | 1 | 1 | Yes | No |
| 16953473 | METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM | November 2020 | February 2024 | Allow | 39 | 1 | 1 | No | No |
| 16953068 | MODIFIED GAMMA DELTA T CELLS AND USES THEREOF | November 2020 | May 2024 | Abandon | 41 | 1 | 1 | No | No |
| 16950244 | USE OF SMALL MOLECULES TO ENHANCE MAFA EXPRESSION IN PANCREATIC ENDOCRINE CELLS | November 2020 | January 2024 | Allow | 38 | 1 | 1 | No | No |
| 17099421 | METHODS AND COMPOSITIONS FOR TREATMENT OF OCULAR DISORDERS AND BLINDING DISEASES | November 2020 | May 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17097815 | RNA TRANSCRIPTION VECTOR AND USES THEREOF | November 2020 | July 2024 | Abandon | 54 | 2 | 1 | No | No |
| 17089474 | CANCER IMMUNOTHERAPY USING CD19-DIRECTED CHIMERIC ANTIGEN RECEPTORS | November 2020 | August 2021 | Allow | 9 | 1 | 0 | Yes | No |
| 17077782 | CHIMERIC ANTIGEN RECEPTOR | October 2020 | July 2023 | Abandon | 33 | 1 | 0 | No | No |
| 17077545 | TRANSGENIC ANIMALS AND METHODS OF USE | October 2020 | May 2024 | Allow | 43 | 1 | 1 | Yes | No |
| 17071574 | NON-INVASIVE, IN VITRO FUNCTIONAL TISSUE ASSAY SYSTEMS | October 2020 | June 2023 | Allow | 32 | 1 | 0 | No | No |
| 17031367 | NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS | September 2020 | June 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17030057 | ENHANCED IMMUNOGLOBULIN DIVERSITY | September 2020 | September 2023 | Allow | 36 | 1 | 1 | Yes | No |
| 17021240 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | September 2020 | July 2021 | Allow | 10 | 1 | 1 | No | No |
| 17021234 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | September 2020 | July 2021 | Allow | 10 | 1 | 1 | No | No |
| 17021238 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | September 2020 | December 2023 | Abandon | 39 | 1 | 1 | No | No |
| 17021242 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | September 2020 | December 2023 | Abandon | 39 | 1 | 1 | No | No |
| 17015947 | METHOD FOR INDUCING A TOLEROGENIC IMMUNE RESPONSE | September 2020 | June 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 16979458 | Improved Oncolytic Reovirus | September 2020 | March 2025 | Allow | 54 | 2 | 1 | Yes | No |
| 17013830 | MICROENVIRONMENTS FOR SELF-ASSEMBLY OF ISLET ORGANOIDS FROM STEM CELLS DIFFERENTIATION | September 2020 | January 2024 | Allow | 40 | 1 | 1 | No | No |
| 17013135 | UNIVERSAL DONOR CELLS | September 2020 | May 2021 | Allow | 9 | 1 | 1 | Yes | No |
| 17012651 | GENERATING HUMAN PODOCYTE CELLS | September 2020 | February 2024 | Allow | 41 | 1 | 1 | No | No |
| 16977506 | CLOSED-ENDED DNA (CEDNA) VECTORS FOR INSERTION OF TRANSGENES AT GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMES | September 2020 | June 2025 | Abandon | 58 | 2 | 1 | No | No |
| 17009279 | PRODUCTION AND USE OF RED BLOOD CELLS | September 2020 | December 2023 | Abandon | 39 | 2 | 0 | No | No |
| 17004698 | POPULATION CONTROL USING ENGINEERED TRANSLOCATIONS | August 2020 | September 2024 | Allow | 49 | 2 | 1 | Yes | No |
| 17000140 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF | August 2020 | May 2023 | Allow | 33 | 1 | 0 | No | No |
| 16997184 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | August 2020 | November 2021 | Allow | 15 | 2 | 1 | Yes | No |
| 16995372 | TRANSGENIC SILKWORMS EXPRESSING HAGFISH THREAD KERATIN | August 2020 | March 2024 | Allow | 43 | 2 | 1 | Yes | No |
| 16993160 | METHOD FOR GENERATING IMMUNE CELLS RESISTANT TO ARGININE AND/OR TRYPTOPHAN DEPLETED MICROENVIRONMENT | August 2020 | August 2024 | Allow | 48 | 2 | 1 | Yes | No |
| 16968317 | PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME | August 2020 | June 2022 | Allow | 23 | 2 | 1 | Yes | Yes |
| 16934848 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | July 2020 | April 2021 | Allow | 9 | 2 | 1 | Yes | No |
| 16934412 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | July 2020 | July 2021 | Allow | 12 | 1 | 1 | Yes | No |
| 16934885 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | July 2020 | April 2021 | Allow | 9 | 2 | 1 | Yes | No |
| 16934764 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | July 2020 | April 2021 | Allow | 9 | 1 | 1 | No | No |
| 16962973 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture | July 2020 | April 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16920286 | INDIVIDUALIZED VACCINES FOR CANCER | July 2020 | October 2021 | Allow | 15 | 1 | 0 | Yes | No |
| 16912084 | BACULOVIRUS EXPRESSION SYSTEM | June 2020 | May 2023 | Allow | 34 | 4 | 1 | Yes | No |
| 16892106 | METHODS FOR MAKING INSULIN IN VIVO | June 2020 | January 2023 | Abandon | 32 | 1 | 0 | No | No |
| 16767527 | CELL CULTURE CONTAINER CAPABLE OF LONG-TERM CULTURE AND METHOD FOR MANUFACTURING SAME | May 2020 | April 2024 | Abandon | 46 | 0 | 1 | No | No |
| 16858435 | AAV/XBP1S-HA VIRUS, GENE THERAPY METHOD AND USE THEREOF IN THE OPTIMISATION AND IMPROVEMENT OF LEARNING, MEMORY AND COGNITIVE CAPACITIES | April 2020 | May 2024 | Abandon | 48 | 2 | 1 | Yes | No |
| 16849847 | TRANSGENIC MAMMALS AND METHODS OF USE THEREOF | April 2020 | March 2024 | Allow | 47 | 1 | 1 | Yes | No |
| 16844657 | PROTECTED GUIDE RNAS (PGRNAS) | April 2020 | November 2022 | Allow | 31 | 1 | 0 | Yes | No |
| 16844548 | OPTIMIZED CRISPR-CAS DOUBLE NICKASE SYSTEMS, METHODS AND COMPOSITIONS FOR SEQUENCE MANIPULATION | April 2020 | November 2022 | Allow | 31 | 1 | 0 | No | No |
| 16817413 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | March 2020 | October 2023 | Allow | 43 | 3 | 0 | Yes | No |
| 16793896 | METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM | February 2020 | November 2020 | Allow | 9 | 1 | 0 | No | No |
| 16793918 | METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM | February 2020 | January 2022 | Allow | 23 | 1 | 0 | No | No |
| 16794115 | MITOCHONDRIAL TRANSPLANTATION TO ALTER ENERGY METABOLISM | February 2020 | December 2022 | Abandon | 34 | 1 | 1 | No | No |
| 16790246 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | February 2020 | August 2020 | Allow | 6 | 1 | 0 | No | No |
| 16790263 | GENETIC ENGINEERING OF NON-HUMAN ANIMALS FOR THE PRODUCTION OF CHIMERIC ANTIBODIES | February 2020 | September 2020 | Allow | 7 | 1 | 0 | No | No |
| 16745873 | CHIMERIC CAPSIDS | January 2020 | August 2024 | Allow | 55 | 2 | 1 | Yes | No |
| 16735683 | COMPOUNDS, COMPOSITIONS, METHODS, AND KITS RELATING TO TELOMERE EXTENSION | January 2020 | July 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16735684 | COMPOUNDS, COMPOSITIONS, METHODS, AND KITS RELATING TO TELOMERE EXTENSION | January 2020 | February 2024 | Allow | 50 | 1 | 1 | No | No |
| 16729852 | HUMANIZED LIGHT CHAIN MICE | December 2019 | November 2022 | Allow | 34 | 1 | 0 | No | No |
| 16729798 | HUMANIZED LIGHT CHAIN MICE | December 2019 | November 2022 | Allow | 35 | 1 | 0 | No | No |
| 16717923 | METHODS OF MAKING HUMAN PRIMITIVE ECTODERM CELLS | December 2019 | February 2023 | Allow | 38 | 1 | 1 | No | No |
| 16708180 | DRUG RESISTANT IMMUNOTHERAPY FOR TREATMENT OF A CANCER | December 2019 | September 2024 | Allow | 58 | 3 | 0 | No | No |
| 16707223 | GENE-THERAPY VECTORS FOR TREATING CARDIOMYOPATHY | December 2019 | May 2023 | Allow | 41 | 1 | 1 | Yes | No |
| 16694040 | EFFICIENT INDUCTION OF DEFINITIVE ENDODERM FROM PLURIPOTENT STEM CELLS | November 2019 | December 2023 | Abandon | 49 | 3 | 0 | Yes | No |
| 16614170 | A TRANSGENIC INVERTEBRATE MODEL FOR ALZHEIMER'S DISEASE AND USE THEREOF | November 2019 | October 2023 | Allow | 47 | 2 | 1 | Yes | No |
| 16682541 | Differentiation of Pluripotent Stem Cells to Form Renal Organoids | November 2019 | July 2024 | Allow | 56 | 2 | 1 | Yes | No |
| 16679100 | METHODS OF PRODUCING PANCREATIC HORMONES | November 2019 | June 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16611781 | ACCELERATION OF STEM CELL DIFFERENTIATION | November 2019 | February 2023 | Allow | 39 | 1 | 1 | Yes | No |
| 16676196 | DNA VACCINES AND METHODS FOR THE PREVENTION OF TRANSPLANTATION REJECTION | November 2019 | August 2023 | Abandon | 45 | 1 | 1 | No | No |
| 16665892 | COMPOUNDS FOR IMPROVED VIRAL TRANSDUCTION | October 2019 | October 2020 | Allow | 11 | 1 | 0 | No | No |
| 16657428 | CD34+,CD45- PLACENTAL STEM CELL-ENRICHED CELL POPULATIONS | October 2019 | October 2023 | Abandon | 48 | 2 | 0 | No | No |
| 16657202 | TRIPLOID SHELLFISH | October 2019 | January 2024 | Abandon | 51 | 3 | 1 | Yes | No |
| 16606120 | ANTIGEN-SPECIFIC IMMUNE EFFECTOR CELLS | October 2019 | July 2024 | Allow | 57 | 3 | 1 | Yes | No |
| 16599620 | METHODS AND SYSTEMS FOR CONVERTING PRECURSOR CELLS INTO INTESTINAL TISSUES THROUGH DIRECTED DIFFERENTIATION | October 2019 | August 2024 | Allow | 58 | 3 | 0 | Yes | No |
| 16598920 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | October 2019 | March 2023 | Allow | 41 | 2 | 0 | No | No |
| 16586786 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS | September 2019 | July 2022 | Allow | 34 | 1 | 0 | Yes | No |
| 16498831 | ADDITION OF NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND CLEARANCE OF HOST CELL NUCLEIC ACIDS | September 2019 | November 2023 | Abandon | 49 | 2 | 0 | No | No |
| 16582279 | PANCREATIC ENDOCRINE CELLS AND METHODS THEREOF | September 2019 | September 2023 | Allow | 48 | 3 | 0 | Yes | No |
| 16583135 | PDX1 POSITIVE FOREGUT ENDODERM CELLS AND METHODS OF PRODUCTION | September 2019 | December 2022 | Allow | 38 | 1 | 0 | No | No |
| 16579396 | Alphavirus Replicon Particles Expressing TRP2 | September 2019 | January 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16573985 | SERUM-FREE IN VITRO DIRECTED DIFFERENTIATION PROTOCOL FOR GENERATING STEM CELL-DERIVED BETA CELLS AND USES THEREOF | September 2019 | December 2023 | Abandon | 50 | 3 | 0 | Yes | No |
| 16493877 | INDUCED TOTIPOTENT STEM CELLS AND METHODS FOR MAKING AND USING THE SAME | September 2019 | September 2022 | Abandon | 36 | 0 | 1 | No | No |
| 16568116 | TARGETED REPLACEMENT OF ENDOGENOUS T CELL RECEPTORS | September 2019 | January 2021 | Allow | 16 | 1 | 1 | Yes | No |
| 16490394 | PANCREATIC PROGENITOR CELL PRODUCTION METHOD | August 2019 | November 2022 | Abandon | 38 | 0 | 1 | No | No |
| 16544993 | MAINTENANCE CULTURE OF INDUCED PLURIPOTENT STEM CELL-DERIVED INTESTINAL STEM CELLS | August 2019 | March 2023 | Allow | 43 | 1 | 1 | Yes | No |
| 16486360 | MAMMALIAN CELLS FOR PRODUCING ADENO-ASSOCIATED VIRUSES | August 2019 | June 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16539401 | METHODS FOR LOWERING BLOOD GLUCOSE | August 2019 | February 2022 | Allow | 30 | 1 | 0 | No | No |
| 16530777 | Generation of Human Spinal Cord Neural Stem Cells | August 2019 | May 2023 | Allow | 46 | 2 | 1 | Yes | No |
| 16528803 | METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF | August 2019 | February 2022 | Allow | 31 | 1 | 1 | No | No |
| 16481418 | ENDODERMAL CELL POPULATION, AND METHOD FOR PRODUCING CELL POPULATION OF ANY OF THREE GERM LAYERS FROM PLURIPOTENT CELL | July 2019 | May 2023 | Allow | 46 | 2 | 1 | No | No |
| 16480025 | MEDIA AND METHODS FOR ENHANCING THE SURVIVAL AND PROLIFERATION OF STEM CELLS | July 2019 | February 2023 | Allow | 43 | 3 | 1 | Yes | No |
| 16478307 | Maintenance and Expansion of Pancreatic Progenitor Cells | July 2019 | May 2023 | Abandon | 46 | 2 | 0 | No | No |
| 16458740 | CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER | July 2019 | January 2022 | Allow | 31 | 1 | 1 | Yes | No |
| 16445124 | METHODS OF MAKING AND USING PDX1-POSITIVE PANCREATIC ENDODERM CELLS | June 2019 | October 2021 | Allow | 28 | 1 | 1 | No | No |
| 16436545 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC SIRPa | June 2019 | February 2021 | Allow | 20 | 1 | 1 | Yes | No |
| 16435428 | DIFFERENTIATION OF HUMAN EMBRYONIC STEM CELLS INTO SINGLE HORMONAL INSULIN POSITIVE CELLS | June 2019 | February 2022 | Allow | 32 | 1 | 1 | No | No |
| 16432026 | CERAMIDASE AND CELL DIFFERENTIATION | June 2019 | July 2023 | Abandon | 49 | 2 | 1 | No | No |
| 16429978 | LATE-ONSET ALZHEIMER'S DISEASE ANIMAL MODEL AND USES THEREOF | June 2019 | January 2024 | Allow | 55 | 2 | 1 | No | No |
| 16418893 | METHODS AND SYSTEMS FOR GUIDE RNA DESIGN AND USE | May 2019 | January 2022 | Allow | 32 | 3 | 1 | Yes | No |
| 16416580 | A METHOD TO DIRECT DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO FUNCTIONAL HEART MUSCLE | May 2019 | March 2023 | Abandon | 46 | 1 | 1 | No | No |
| 16415309 | CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER | May 2019 | August 2021 | Allow | 27 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner MONTANARI, DAVID A.
With a 46.2% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 31.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner MONTANARI, DAVID A works in Art Unit 1632 and has examined 782 patent applications in our dataset. With an allowance rate of 58.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 41 months.
Examiner MONTANARI, DAVID A's allowance rate of 58.2% places them in the 20% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by MONTANARI, DAVID A receive 2.43 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by MONTANARI, DAVID A is 41 months. This places the examiner in the 20% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +52.8% benefit to allowance rate for applications examined by MONTANARI, DAVID A. This interview benefit is in the 94% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 23% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 37.2% of cases where such amendments are filed. This entry rate is in the 57% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 46.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 84.5% of appeals filed. This is in the 78% percentile among all examiners. Of these withdrawals, 81.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 79.5% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 9.1% of allowed cases (in the 93% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 56% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.